EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Youssra Salhi iD, Stavros Makrodimitris iD, Sandra van Wilpe, Iris Te Paske, Vanja de Weerd, Corine M Beaufort, Hans M Westgeest, Jens Voortman, Maureen J B Aarts, Maud Rijnders, Astrid A M van der Veldt, Ronald de Wit und 3 weitere

Molecular Oncology · 2026

DOI: 10.1002/1878-0261.70272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Youssra Salhi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Aneuploidy, Circulating Tumor DNA, Antineoplastic Agents, Immunological. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp and Dohme United Kingdom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate prediction of lack of benefit from pembrolizumab in patients with metastatic urothelial cancer (mUC) is an unmet need. We investigated the dynamics of circulating tumor DNA (ctDNA) load, estimated using the modified fast aneuploidy screening test‐sequencing system (mFast‐SeqS), as a potential biomarker for early on‐treatment identification of treatment response. A total of 104 patients with mUC treated with pembrolizumab from two prospective biomarker discovery trials were included and mFast‐SeqS was performed on paired blood samples collected at baseline and on‐treatment. Patients with a high on‐treatment aneuploidy score (≥ 5, n = 26) had a shorter median OS than patients with a low (< 5) score ( n = 76) (3 vs 17 months: P ‐value< 0.001). Patients with an increased ( n = 10), stable ( n = 66), or decreased ( n = 28) on‐treatment score relative to their baseline score had a median PFS of 1.5, 4.0, and 8.3 months, respectively. Median OS was 3.0, 11.1, and 18.7 months, respectively. In patients with mUC treated with pembrolizumab, the on‐treatment mFast‐SeqS‐based ctDNA level and its dynamics relative to baseline are independent prognostic markers that can be used to identify patients that are unlikely to benefit from pembrolizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAneuploidyCirculating Tumor DNAAntineoplastic Agents, ImmunologicalUrologic NeoplasmsCell-Free Nucleic AcidsUrotheliumUrinary Bladder NeoplasmsHumansFemaleMaleAgedMiddle AgedNeoplasm MetastasisBiomarkers, TumorLongitudinal StudiesAged, 80 and over

Stichwörter der Autor:innen

circulating tumor DNAmetastatic urothelial cancermodified fast aneuploidy screening test‐sequencing systempembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabCirculating Tumor DNABiomarkers, TumorAntineoplastic Agents, ImmunologicalCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Medical Oncology, Amphia Hospital Breda, The Netherlands.
  • Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
  • Department of Medical Oncology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, The Netherlands.
  • Department of Internal Medicine, Franciscus Gasthuis & Vlietland Rotterdam, The Netherlands.

ORCID-Profile: Youssra Salhi, Stavros Makrodimitris

Förderung

  • Merck Sharp and Dohme United Kingdom

Zitieren

APA

Salhi, Y., Makrodimitris, S., van Wilpe, S., Te Paske, I., de Weerd, V., Beaufort, C. M., Westgeest, H. M., Voortman, J., Aarts, M. J. B., Rijnders, M., van der Veldt, A. A. M., de Wit, R., Mehra, N., Wilting, S. M., & Robbrecht, D. G. J. (2026). Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.70272

Vancouver

Salhi Y, Makrodimitris S, van Wilpe S, Te Paske I, de Weerd V, Beaufort CM, et al. Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer. Molecular Oncology. 2026. doi:10.1002/1878-0261.70272

BibTeX
@article{Salhi2026,
  author = {Salhi, Youssra and Makrodimitris, Stavros and van Wilpe, Sandra and Te Paske, Iris and de Weerd, Vanja and Beaufort, Corine M and Westgeest, Hans M and Voortman, Jens and Aarts, Maureen J B and Rijnders, Maud and van der Veldt, Astrid A M and de Wit, Ronald and Mehra, Niven and Wilting, Saskia M and Robbrecht, Debbie G J},
  title = {Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70272}
}
Kostenlos starten →